Please login to the form below

Farxiga

This page shows the latest Farxiga news and features for those working in and with pharma, biotech and healthcare.

AZ says target of $45bn sales by 2023 still achievable

AZ’s CEO also highlighted diabetes therapy Farxiga (dapagliflozin), which grew by a third to $994m in the nine-month period despite a tough competitive environment. ... The study showed Farxiga cut hospitalisations for heart failure and cardiovascular

Latest news

New cancer drugs can’t quite plug the revenue hole at AZ

Other bright spots for AZ included the continued growth if antiplatelet drug Brilinta (ticagrelor), up 18% to $609m, diabetes drug Farxiga (dapagliflozin) which leaped 36% to $639m, and new asthma drug
J&J’s Invokana aces diabetic kidney disease trial, setting up filings

risk of lower-limb amputation in diabetics, putting it at a disadvantage compared to rival SGLT2 drugs such as Eli Lilly and Boehringer Ingelheim's Jardiance (empagliflozin) and AstraZeneca’s Farxiga
J&J says real-world data finds no amputation risk for Invokana

Meanwhile, AstraZeneca’s Farxiga (dapagliflozin) has also continued to gather pace with the company reporting sales rose 29% to just over $1bn last year.
The year of the blockbuster

entrant to an increasingly crowded market and will compete directly with first-to-market Invokana, as well as Farxiga and Jardiance.
FDA starts review of Sanofi’s oral type 1 diabetes drug

Ingelheim's Jardiance and Farxiga from AstraZeneca.

More from news
Approximately 4 fully matching, plus 22 partially matching documents found.

Latest Intelligence

China: AstraZeneca’s new engine for growth and innovation

One of its latest launches in the country is Farxiga, its contender in the SGLT2 inhibitor diabetes market.
Transforming times at AstraZeneca

and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer (Remote Working): Competitive Salary Offered

Medical Writers: Competitive Salary and Benefits

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

New Business Director - PR: Competitive Salary and benefits

Associate Director: £75, 000-90, 000

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

Production Manager – Healthcare Communications: DOE

Account Manager, Healthcare Communications: £32, 000 - £40, 000 benefits

Associate Director, Market Access & HEOR – North-West: Negotiable

Associate Medical Director: Highly Competitive

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Account Executive, London, Medical Communications: Excellent package

Senior Account Manager- Central Oxford and Abingdon: Negotiable

Senior Medical Writer: Great salary and benefits

Project / Account Manager (Medical Education): Salary TBC

Account Director: Excellent benefits

Medical/ Scientific Director: Salary TBC

Consultant Health Economics - London / Oxford: Negotiable

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Medical Writers Required – Cheshire: DOE

Senior Medical Writer: Competitive Salary

Consumer Health Account Director: Circa £60, 000 Gym and More

Subscribe to our email news alerts

PMHub

Add my company

emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Quality in Care Diabetes 2018: the best in innovative diabetes care: Awards highlight new evidence-based approaches to improving care...